The Week in Diabetes & Endocrinology — Episode 001 | April 3, 2026

From Hormone Insight (hormoneinsight.com)

Six stories this week that endocrinologists, diabetologists, and internists need to know.

TIMESTAMPS:

0:00 — Introduction & This Week's Stories

1:30 — Orforglipron (Foundayo) FDA Approval: The Oral GLP-1 Pill — Access-Changer, Not Game-Changer

7:00 — Semaglutide 7.2 mg (Wegovy HD): 21% Weight Loss, But Watch the Dysesthesia Signal

11:30 — Insulin Icodec (Awiqli): Once-Weekly Insulin — Sounds Great Until You Think About Sick Days

16:00 — SURPASS-CVOT Post-Hoc in JAMA Cardiology: Tirzepatide's Cardiorenal NNT of 27

19:30 — AACE 2026 Type 2 Diabetes Algorithm Update

21:30 — GLP-1 RAs in Parkinson's Disease: 5 RCTs, 708 Patients, No Signal

24:00 — Closing Thoughts

REFERENCES & SHOW NOTES:

▸ Orforglipron FDA approval: https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026

▸ Wegovy HD FDA approval: https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide

▸ Awiqli FDA approval: https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-awiqli-the-first-and-only-once-weekly-basal-insulin-treatment-for-adults-with-type-2-diabetes-302726839.html

▸ Nissen SE et al. JAMA Cardiol 2026 — SURPASS-CVOT cardiorenal post-hoc: https://doi.org/10.1001/jamacardio.2026.0767

▸ Nicholls SJ et al. N Engl J Med 2025 — SURPASS-CVOT primary: https://doi.org/10.1056/NEJMoa2505928

▸ AACE 2026 T2D Algorithm: https://www.sciencedirect.com/science/article/pii/S1530891X26000224

▸ Raza H et al. Brain Behav 2026 — GLP-1 RAs in Parkinson's: https://doi.org/10.1002/brb3.71344

ABOUT THIS PODCAST:

A weekly evidence-based review of the top stories in diabetes, obesity, thyroid, and endocrinology — modeled on Medscape's "This Week in Cardiology." New episodes every Thursday. For healthcare professionals.

▸ Website: https://hormoneinsight.com

▸ Full show notes: https://hormoneinsight.com/podcast

️ This content is intended for healthcare professionals. It does not constitute medical advice for patients.

#Endocrinology #DiabetesResearch #GLP1 #Orforglipron #Foundayo #WegovyHD #Semaglutide #InsulinIcodec #Awiqli #Tirzepatide #SURPASSCVOT #ObesityMedicine #Type2Diabetes #ClinicalTrials #EvidenceBasedMedicine #MedicalPodcast #HormoneInsight #EndocrinologyPodcast #Diabetology #CME #MedTwitter #DoctorsOfYouTube #InternalMedicine #Cardiology #CardiometabolicHealth #WeeklyInsulin #OralGLP1 #ParkinsonsDisease #AACE #PhysicianEducation